Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Cash Flow: 2019-2025

Historic Net Cash Flow for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -$19.3 million.

  • C4 Therapeutics' Net Cash Flow fell 43.69% to -$19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$840,000, marking a year-over-year increase of 36.98%. This contributed to the annual value of -$71.1 million for FY2024, which is 173.29% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Net Cash Flow is -$19.3 million, which was down 172.02% from $26.9 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Net Cash Flow peaked at $184.9 million during Q2 2021, and registered a low of -$118.4 million during Q3 2021.
  • For the 3-year period, C4 Therapeutics' Net Cash Flow averaged around $2.7 million, with its median value being -$4.2 million (2025).
  • Data for C4 Therapeutics' Net Cash Flow shows a peak YoY increase of 447.19% (in 2021) and a maximum YoY decrease of 420.04% (in 2021) over the last 5 years.
  • C4 Therapeutics' Net Cash Flow (Quarterly) stood at -$84.6 million in 2021, then soared by 76.60% to -$19.8 million in 2022, then surged by 431.40% to $65.6 million in 2023, then slumped by 106.33% to -$4.2 million in 2024, then tumbled by 43.69% to -$19.3 million in 2025.
  • Its Net Cash Flow was -$19.3 million in Q3 2025, compared to $26.9 million in Q2 2025 and -$4.2 million in Q1 2025.